[Ip-health] US India Joint Statement
Reji K. Joseph
rejikjoseph at gmail.com
Thu Oct 2 18:33:22 PDT 2014
Dear Mr. Carter,
Please attach the excel file; it was missing.
On Thu, Oct 2, 2014 at 7:59 PM, George Carter <fiar at verizon.net> wrote:
> We are trying to see if any of the companies in the attached excel file
> are generally reputable. They make both sofosbuvir and daclatasvir,
> probably one of the best DAA combos. I realize they may be producing the
> API only. But that would be a good start. It is a relatively simple matter,
> tho not inexpensive, to test for identity, potency and purity. Assuring
> bioequivalence in terms of excipients, fillers, etc., would be step two.
> Step three would be assuring access to those denied treatment.
> While much of the focus is on the unlicensed nations and LMICs, there are
> MILLIONS of people in upper income countries like me who have to wait til
> our livers are on the verge of exploding before we're permitted by Gilead's
> death panels to receive medical treatment.
> Any help or insights greatly appreciated. Sadly, Gilead probably knows
> about these companies and is no doubt working hard to destroy them, as they
> are destroying millions of lives around the world to feed their insatiable,
> extortionate greed.
> George M. Carter
> Ip-health mailing list
> Ip-health at lists.keionline.org
Reji K. Joseph, PhD (Economics)
Centre for Studies in International Politics and Governance
Central University of Gujarat
Gandhinagar - 382030, Gujarat, INDIA.
Phone: +91-8469099299 (Mob.)
Office email: rejikjoseph at cug.ac.in
More information about the Ip-health